Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Exposure source for skin sensitizing hydroperoxides of limonene and linalool remains elusive: An analytical market surveillance.

Natsch A, Nägelin M, Leijs H, van Strien M, Giménez-Arnau E, Vey M, González C.

Food Chem Toxicol. 2019 May;127:156-162. doi: 10.1016/j.fct.2019.03.028. Epub 2019 Mar 21.

PMID:
30905868
2.

Quantification of selected furocoumarins by high-performance liquid chromatography and UV-detection: capabilities and limits.

Macmaster AP, Owen N, Brussaux S, Brevard H, Hiserodt R, Leijs H, Bast N, Weber B, Loesing G, Sherlock A, Schippa C, Vey M, Frérot E, Tissot E, Chaintreau A.

J Chromatogr A. 2012 Sep 28;1257:34-40. doi: 10.1016/j.chroma.2012.07.048. Epub 2012 Jul 25.

PMID:
22926051
3.

Studies on the dissociation of botulinum neurotoxin type A complexes.

Eisele KH, Fink K, Vey M, Taylor HV.

Toxicon. 2011 Mar 15;57(4):555-65. doi: 10.1016/j.toxicon.2010.12.019. Epub 2010 Dec 30.

PMID:
21195107
4.

The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting.

Adler S, Bicker G, Bigalke H, Bishop C, Blümel J, Dressler D, Fitzgerald J, Gessler F, Heuschen H, Kegel B, Luch A, Milne C, Pickett A, Ratsch H, Ruhdel I, Sesardic D, Stephens M, Stiens G, Thornton PD, Thürmer R, Vey M, Spielmann H, Grune B, Liebsch M.

Altern Lab Anim. 2010 Aug;38(4):315-30. No abstract available.

PMID:
20822324
5.

A new IFRA Standard on the fragrance ingredient, hydroxyisohexyl 3-cyclohexene carboxaldehyde.

Api AM, Vey M.

Contact Dermatitis. 2010 Apr;62(4):254-5. doi: 10.1111/j.1600-0536.2010.01701.x. No abstract available.

PMID:
20433450
6.

Experimental conditions substantially influence botulinum toxin potency testing.

Mander G, Fink K, Vey M.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):234; author reply 235. doi: 10.1097/WNF.0b013e3181acef9b. No abstract available.

PMID:
19644233
7.

The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes.

Polymenidou M, Moos R, Scott M, Sigurdson C, Shi YZ, Yajima B, Hafner-Bratkovic I, Jerala R, Hornemann S, Wuthrich K, Bellon A, Vey M, Garen G, James MN, Kav N, Aguzzi A.

PLoS One. 2008;3(12):e3872. doi: 10.1371/journal.pone.0003872. Epub 2008 Dec 8.

8.

Special issue on QRA.

Api AM, Vey M.

Regul Toxicol Pharmacol. 2008 Oct;52(1):1-2. doi: 10.1016/j.yrtph.2008.08.016. No abstract available.

PMID:
18971028
9.

Implementation of the dermal sensitization Quantitative Risk Assessment (QRA) for fragrance ingredients.

Api AM, Vey M.

Regul Toxicol Pharmacol. 2008 Oct;52(1):53-61. doi: 10.1016/j.yrtph.2008.05.011. Epub 2008 May 27.

PMID:
18635300
10.

Personality and emotional performance: extraversion, neuroticism, and self-monitoring.

Bono JE, Vey MA.

J Occup Health Psychol. 2007 Apr;12(2):177-92.

PMID:
17469999
11.

GC-MS quantification of suspected volatile allergens in fragrances. 2. Data treatment strategies and method performances.

Bassereau M, Chaintreau A, Duperrex S, Joulain D, Leijs H, Loesing G, Owen N, Sherlock A, Schippa C, Thorel PJ, Vey M.

J Agric Food Chem. 2007 Jan 10;55(1):25-31.

PMID:
17199309
12.

Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease.

Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A.

Lancet Neurol. 2005 Dec;4(12):805-14. Erratum in: Lancet Neurol. 2005 Dec;4(12):795.

PMID:
16297838
13.

Diagnosis of human prion disease.

Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, Serban A, Vey M, Baron H, Giles K, Miller BL, Dearmond SJ, Prusiner SB.

Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3501-6.

15.

Standards for the assay of Creutzfeldt-Jakob disease specimens.

Minor P, Newham J, Jones N, Bergeron C, Gregori L, Asher D, van Engelenburg F, Stroebel T, Vey M, Barnard G, Head M; WHO Working Group on International Reference Materials for the Diagnosis and Study of Transmissible Spongiform Encephalopathies.

J Gen Virol. 2004 Jun;85(Pt 6):1777-84.

PMID:
15166463
16.

GC-MS quantitation of fragrance compounds suspected to cause skin reactions. 1.

Chaintreau A, Joulain D, Marin C, Schmidt CO, Vey M.

J Agric Food Chem. 2003 Oct 22;51(22):6398-403.

PMID:
14558753
17.

Trafficking of prion proteins through a caveolae-mediated endosomal pathway.

Peters PJ, Mironov A Jr, Peretz D, van Donselaar E, Leclerc E, Erpel S, DeArmond SJ, Burton DR, Williamson RA, Vey M, Prusiner SB.

J Cell Biol. 2003 Aug 18;162(4):703-17.

18.

Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity.

Bellon A, Seyfert-Brandt W, Lang W, Baron H, Gröner A, Vey M.

J Gen Virol. 2003 Jul;84(Pt 7):1921-5.

PMID:
12810888
19.

Procedure for supplying fragrance information promptly to dermatologists.

Vey M.

Contact Dermatitis. 2003 Jan;48(1):56-8. No abstract available.

PMID:
12641586
20.

Procedures for supplying fragrance information to dermatologists.

Roberts G, Vey M; International Fragnance Association.

Am J Contact Dermat. 2002 Dec;13(4):206-7. No abstract available.

PMID:
12484386
21.

Consumer exposure to fragrance ingredients: providing estimates for safety evaluation.

Cadby PA, Troy WR, Vey MG.

Regul Toxicol Pharmacol. 2002 Dec;36(3):246-52. Review.

PMID:
12473409
22.

Purity of spiking agent affects partitioning of prions in plasma protein purification.

Vey M, Baron H, Weimer T, Gröner A.

Biologicals. 2002 Sep;30(3):187-96.

PMID:
12217343
23.

COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform.

Kaneko K, Vey M, Scott M, Pilkuhn S, Cohen FE, Prusiner SB.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2333-8.

24.

Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains.

Vey M, Pilkuhn S, Wille H, Nixon R, DeArmond SJ, Smart EJ, Anderson RG, Taraboulos A, Prusiner SB.

Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14945-9.

25.

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system.

Yamshchikov GV, Ritter GD, Vey M, Compans RW.

Virology. 1995 Dec 1;214(1):50-8.

26.

Two independent targeting signals in the cytoplasmic domain determine trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin.

Schäfer W, Stroh A, Berghöfer S, Seiler J, Vey M, Kruse ML, Kern HF, Klenk HD, Garten W.

EMBO J. 1995 Jun 1;14(11):2424-35.

27.

Endoproteolytic cleavage of its propeptide is a prerequisite for efficient transport of furin out of the endoplasmic reticulum.

Creemers JW, Vey M, Schäfer W, Ayoubi TA, Roebroek AJ, Klenk HD, Garten W, Van de Ven WJ.

J Biol Chem. 1995 Feb 10;270(6):2695-702.

28.

Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin.

Vey M, Schäfer W, Reis B, Ohuchi R, Britt W, Garten W, Klenk HD, Radsak K.

Virology. 1995 Jan 10;206(1):746-9.

29.
30.
31.

Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones.

Garten W, Hallenberger S, Ortmann D, Schäfer W, Vey M, Angliker H, Shaw E, Klenk HD.

Biochimie. 1994;76(3-4):217-25. Review.

PMID:
7819326
32.

Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease.

Stieneke-Gröber A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk HD, Garten W.

EMBO J. 1992 Jul;11(7):2407-14.

33.

Hemagglutinin activation of pathogenic avian influenza viruses of serotype H7 requires the protease recognition motif R-X-K/R-R.

Vey M, Orlich M, Adler S, Klenk HD, Rott R, Garten W.

Virology. 1992 May;188(1):408-13.

PMID:
1566583
34.

Modification of the cleavage activation of the influenza virus hemagglutinin by site-specific mutagenesis.

Garten W, Vey M, Ohuchi R, Ohuchi M, Klenk HD.

Behring Inst Mitt. 1991 Jul;(89):12-22.

PMID:
1930091
35.

Hemispheric control of the writing hand: the effect of callosotomy in a left-hander.

Gur RE, Gur RC, Sussman NM, O'Connor MJ, Vey MM.

Neurology. 1984 Jul;34(7):904-8.

PMID:
6539866
36.

[Septicemic infection by spore forming bacteria in Crustacea, Isotopa].

Yousfi MA, Vey MA.

Arch Inst Pasteur Tunis. 1978 Dec;55(4):419-25. French.

PMID:
756243

Supplemental Content

Support Center